Antiretroviral Therapy Perspective

• Drugs to Avoid in Patients on DOACs DOACs overall have substantially fewer drug-drug interactions than warfarin, but there are still a few to watch out for.
  Medscape Internal Medicine, July 23, 2020
• AIDS 2020 Read clinically focused news coverage of key developments from IAS 2020
  Medscape HIV/AIDS, July 01, 2020
• Long-acting Injectable Cabotegravir for PrEP Is Promising   Dr Paul Sax discusses the interim results from a study on the use of the long-acting injectable cabotegravir for pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.
  Medscape HIV/AIDS, June 23, 2020
• The Promise of Remdesivir for COVID-19 Treatment   WebMD Chief Medical Officer John Whyte talks with Dr Stuart Cohen about remdesivir for the possible treatment of COVID-19 infection, and when we might expect to see the development of a vaccine.
  WebMD, April 30, 2020
• Confronting the HIV Epidemic   Infectious disease experts from UNC Chapel Hill have developed innovative methods to engage young minority men, the fastest-growing HIV-positive population, in the prevention and treatment of HIV.
  Medscape TV, April 28, 2020
• COVID-19 in People With HIV: Commonly Asked Questions   Dr Paul Sax gives answers to some of the most commonly asked questions he has received from patients with HIV.
  Medscape HIV/AIDS, April 03, 2020
• Low-Level Viremia in HIV: When Should We Worry?   Is all low-level viremia in HIV the same, and does it lead to virologic failure? Dr Sax comments on a new study.
  Medscape HIV/AIDS, March 11, 2020
• CROI 2020 Read clinically focused news coverage of key developments from CROI 2020
  Medscape HIV/AIDS, March 06, 2020
• Infectious Diseases in 2020: 5 Areas of Concern   Dr Paul Auwaerter discusses advances made in infectious diseases in 2019 and looks ahead at concerns for the new year.
  Medscape Infectious Diseases, January 14, 2020
• Time to Rethink Renal Dosing of Lamivudine?   Dose reductions of lamivudine may not be necessary for all patients with mild to moderate renal impairment, says Dr Paul Sax.
  Medscape HIV/AIDS, November 18, 2019
• ANAC 2019 Read clinically focused news coverage of key developments from ANAC 2019
  Medscape Nurses, November 04, 2019
• USCA 2019 Read clinically focused news coverage of key developments from UCSA 2019
  Medscape HIV/AIDS, September 03, 2019
• Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  Medscape HIV/AIDS, July 19, 2019
• IAS 2019 Read clinically focused news coverage of key developments from IAS 2019
  Medscape HIV/AIDS, July 12, 2019
• PrEP and Risk for Sexually Transmitted Infections   Dr Paul Sax shares what he thinks is most interesting and useful about the findings that STI risk is elevated in PrEP users.
  Medscape HIV/AIDS, May 03, 2019
• CROI 2019 Read clinically focused news coverage of key developments from CROI 2019
  Medscape HIV/AIDS, February 25, 2019
• Two- vs Three-Drug Initial Therapy for HIV   Dr Paul Sax describes the potential clinical implications of the GEMINI studies.
  Medscape HIV/AIDS, November 26, 2018
• A Precaution About PrEP in HIV Prevention   PrEP can reduce new HIV infections if taken as directed. So why do PrEP failures occur?
  Medscape HIV/AIDS, November 12, 2018
• Preventing HPV in Patients With HIV: New Guidelines A degree of synergism may exist between these two viruses, so prevention of HPV in patients with HIV is critical.
  Medscape HIV/AIDS, October 26, 2018
• HIV 2018 Read clinically focused news coverage of key developments from HIV Glasgow 2018.
  Medscape HIV/AIDS, October 18, 2018